This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
/ / /
/ / /

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.

 

This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.

 

This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

American Diabetes Association (ADA) guidelines:7

  • In people with type 2 diabetes and established atherosclerotic cardiovascular disease, multiple atherosclerotic cardiovascular disease risk factors, or diabetic kidney disease, a sodium–glucose cotransporter 2 inhibitor with demonstrated cardiovascular benefit is recommended to reduce the risk of major adverse cardiovascular events and/or heart failure hospitalization.
  • In people with type 2 diabetes and established atherosclerotic cardiovascular disease or multiple risk factors for atherosclerotic cardiovascular disease, a glucagon-like peptide 1 receptor agonist with demonstrated cardiovascular benefit is recommended to reduce the risk of major adverse cardiovascular events.

American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines:8

  • For adults with T2D with established CVD: The 2022 ADA/EASD consensus report recommends a glucagon-like peptide-1 receptor agonist (GLP-1 RA) should be used to reduce major adverse cardiovascular events (MACE), or a sodium-glucose co-transporter-2 inhibitor (SGLT-2i) With proven benefit should be used to reduce MACE and HF and improve kidney outcomes

Discover how ADA and EASD guidelines can support your treatment choice >

>

ASCVD risk calculator

Now you can calculate the risk of ASCVD in your patients with T2D.

Dr. Roopa Mehta, Prof. Carolyn Lam, and Prof. David Cherney explain the importance of looking beyond HbA1c control, to help manage the risk of ASCVD events.
Guiding patient discussions

Leverage the HCP-patient discussion guide to aid your patient conversations around ASCVD.
Diabetes, What’s Next?

Provide your patients with T2D and CVD a platform that offers fact-checked, curated content about living with these diseases. Refer your patients to this website for guidance on physical and mental wellbeing and tips on how to manage T2D.
Win hearts and minds

Early screening and management of ASCVD using glucose lowering treatments with proven CV benefit, like GLP-1 receptor agonists or SGLT-2 inhibitors is key to help reducing the risk of ASCVD events in people with T2D who have a high risk of established CVD.7,8

 

Look beyond HbA1c control to win the hearts and minds of your patients with T2D.

1.

Low Wang CC, et al. Circulation. 2016;133:2459-2502.

2.

Mosenzon O, et al. Cardiovasc Diabetol. 2021;20:154.

3.

Barquera S, et al. Archives Med Res. 2015;46:328-338.

4.

Echouffo-Tcheugui JB, et al. Eur Heart J. 2018;39:2376-2386.

5.

Almdal T, et al. Arch Intern Med. 2004;164:1422-1426.

6.

Fox CS, et al. JAMA. 2004;292:2495-2499.

7.

Standards of Care in Diabetes-2023. Diabetes Care. 2023 Jan 1;46(Suppl 1):S158-S190.

8.

Buse JB, et al. Diabetes care 2022;45(11):2753–2786.

9.

Ludwig L. et al. Cardiovasc Diabetol. 2020;19:65.

10.

Kristensen SL, et al. Lancet Diabetes Endocrinol. 2019;7:776–785.